Source comparison
CJC-1295 no DAC & Ipamorelin: Peptide Combination Comparison
CJC-1295 no DAC GHRH receptor agonist. Stimulates pituitary somatotrophs to release GH ~30 minutes 100–200 mcg per injection Amplifies endogenous GH pulse amplitude without altering pulse frequency Required. Food delays absorption and reduces Cmax by 30–40% Be
This comparison does not assign a generated winner or score.
- CJC-1295 no DAC
- GHRH receptor agonist. Stimulates pituitary somatotrophs to release GH
- ~30 minutes
- 100–200 mcg per injection
- Amplifies endogenous GH pulse amplitude without altering pulse frequency
- Required. Food delays absorption and reduces Cmax by 30–40%
- Best used in combination with a GHSR agonist like Ipamorelin to create synergistic pulsatile release
- Ipamorelin
- Selective ghrelin receptor (GHSR-1a) agonist. Triggers GH release via hypothalamic pathways
- ~2 hours
- 200–300 mcg per injection
- Increases GH pulse frequency; minimal effect on cortisol or prolactin unlike GHRP-6
- Required. Competitive inhibition from dietary amino acids reduces bioavailability significantly
- Preferred GHRP due to selectivity; does not significantly elevate cortisol or appetite like GHRP-2 or GHRP-6
- CJC-1295 with DAC
- GHRH receptor agonist with drug affinity complex for extended half-life
- ~6–8 days
- 1–2 mg per week
- Sustained elevation of baseline GH levels rather than pulsatile spikes
- Less critical. Long half-life means timing flexibility, but fasted dosing still improves initial absorption
- Not recommended for natural pulsatile GH patterns; DAC modification causes prolonged receptor occupancy that can blunt natural secretion
- GHRP-2
- Non-selective ghrelin receptor agonist
- ~20 minutes
- 100–300 mcg per injection
- Strong GH release but also stimulates cortisol and prolactin
- Required
- Older generation GHRP; effective but less selective than Ipamorelin. Cortisol elevation limits long-term use